Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS News & Events Dec 03, 2021 Press Releases ViaCyte Chief Scientific Officer to Deliver Keynote Address at JDRF Mission Summit SAN DIEGO, December 3, 2021 – ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced today that the Company’s Chief Scientific Officer, Timothy Kieffer, Ph.D., will deliver the keynote address at the 10th JDRF Mission Summit, “Now Is the Time: Come Together,” […] Read More Press Releases Events Select Year All Articles 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Dec 2, 2021 Press Releases ViaCyte’s Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in Two Published Studies Read More Nov 30, 2021 Press Releases ViaCyte Appoints Marty Lorenzo as General Counsel Read More Nov 16, 2021 Press Releases CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes Read More Oct 20, 2021 Press Releases ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit Read More Load More Media Materials Video of Product Candidates ViaCyte Logo About the Documentary: The Human Trial Media Contact Media: media@viacyte.com COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT

Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS Pluripotent Stem Cell Expansion and Differentiation A potential functional cure for type 1 diabetes The potential for cell replacement therapy to effectively treat type 1 diabetes has already been demonstrated by way of donor islet transplant. Despite the demonstrated efficacy of donor islet transplant, this procedure is reserved for the most high-risk patients because of the limited supply of donor (cadaver) islets and the requirement for immunosuppression. We believe that ViaCyte’s breakthrough technology and cell replacement product candidates can address the limitations of donor islet transplants and become a major advancement in the treatment of diabetes. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT